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Long-Term Comparison of Drug-Eluting Stents
and Coronary Artery Bypass Grafting for
Multivessel Coronary Revascularization
5-Year Outcomes From the Asan Medical Center-
Multivessel Revascularization Registry
Duk-Woo Park, MD,* Young-Hak Kim, MD,* Hae-Geun Song, MD,* Jung-Min Ahn, MD,*
Junhyok Oh, MD,* Won-Jang Kim, MD,* Jong-Young Lee, MD,* Soo-Jin Kang, MD,*
Seung-Whan Lee, MD,* Cheol-Whan Lee, MD,* Seong-Wook Park, MD,* Sung-Cheol Yun, PHD,‡
Sung Ho Jung, MD,† Suk-Jung Choo, MD,† Cheol-Hyun Chung, MD,† Jae-Won Lee, MD,†
Seung-Jung Park, MD*
Seoul, Korea
Objectives We performed the long-term (5-year) follow-up of a large cohort of patients who underwent drug-eluting stent
(DES) or coronary artery bypass graft (CABG) surgery for multivessel revascularization.
Background Limited information is available on very long-term outcomes after multivessel DES treatment relative to CABG.
Methods We evaluated 3,042 patients with multivessel disease who received DES (n  1,547) or underwent CABG (n 
1,495) between January 2003 and December 2005, and for whom complete follow-up data were available for a
median 5.6 years (interquartile range: 4.6 to 6.3 years). We compared adverse outcomes (death; a composite
outcome of death, myocardial infarction, or stroke; and repeat revascularization).
Results After adjustment for differences in baseline risk factors, 5-year risk of death (hazard ratio [HR]: 1.00; 95% confi-
dence interval [CI]: 0.76 to 1.32, p  0.99) and the combined risk of death, myocardial infarction, or stroke (HR:
0.97; 95% CI: 0.76 to 1.24, p  0.81) were similar between the DES group and the CABG group. However, the
rates of revascularization were significantly higher in the DES group (HR: 2.93; 95% CI: 2.20 to 3.90, p 
0.001). Similar results were obtained in comparisons of DES with CABG for high-risk clinical and anatomic sub-
groups with diabetes mellitus, abnormal ventricular function, age 65 years or more, and 3-vessel and left main
disease. However, mortality benefit with DES implantation relative to CABG was noted in patients with 2-vessel
disease (HR: 0.57; 95% CI: 0.36 to 0.92, p  0.02).
Conclusions For patients with multivessel disease, DES treatment, compared with CABG, showed similar rates of mortality
and of the composite safety outcomes, but higher rates of revascularization up to 5 years. (J Am Coll Cardiol
2011;57:128–37) © 2011 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.09.022b
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tver the past few years, revascularization of patients with
ultivessel coronary artery disease (CAD) has improved
ignificantly owing to advances in both coronary artery
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010, accepted September 28, 2010.ypass graft surgery (CABG) and percutaneous coronary
ntervention (PCI), contributing to reductions in mortality
nd morbidity (1,2). Especially, PCI involving drug-eluting
tents (DES) is increasingly used to treat complex CAD, for
hich CABG has been regarded historically as the treat-
ent of choice (3). Therefore, with technological advances
nd changes in clinical practice, the respective values and
reatment effects of CABG and PCI needed to be
eassessed.
Several studies have compared outcomes of PCI with
ES and CABG for multivessel CAD (4–13). Most of
hese studies, however, were limited in duration, with
ollow-up within 1 to 3 years. That may result in a
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January 11, 2011:128–37 DES Versus CABG for Multivessel Diseaseisadvantage for CABG, because the apparent benefits of
urgery over PCI in other settings are usually not fully
vident until 1 to 5 years after the procedure. Furthermore,
he long-term safety of DES has been questioned by recent
eports suggesting increased risks of late stent thrombosis,
ortality, and myocardial infarction (MI) (14,15). Therefore,
ery long-term follow-up after DES implantation, as com-
ared to standard CABG, in a large cohort of patients with
ultivessel disease is clinically important.
The Asan-Multivessel (Asan Medical Center-Multivessel
evascularization) Registry was designed to investigate the
real-word” outcomes of PCI with DES and CABG for
atients with multivessel CAD, and the median 3-year
omparative outcomes were previously reported (5). To
btain a more reliable long-term treatment effect of DES
nd CABG, we have now extended the follow-up duration
or the study patients, for whom follow-up data were
vailable for at least 4 years and as long as 7 years.
ethods
tudy population. The Asan-Multivessel Registry is a
ingle-center, prospective study designed to evaluate the
reatment effects of PCI and CABG for multivessel CAD in
linical practice (5). The registry prospectively contains
nformation on patient demographics, coexisting and clini-
al conditions, hemodynamic status, left ventricular func-
ion, the extent of disease, details of the procedures, and
n-hospital and follow-up outcomes. This analysis includes
onsecutive patients with multivessel CAD who received
CI with DES (with or without other devices) or under-
ent isolated CABG at the Asan Medical Center (Seoul,
orea) during the period from January 1, 2003, through
ecember 31, 2005. The follow-up period was extended
hrough January 31, 2010, to ensure that all patients had an
pportunity for at least 4 years and approximately as many
s 7 years of follow-up information.
Patients who had prior CABG, those who underwent
oncomitant valvular or aortic surgery, and those who had
n acute MI within 24 h before revascularization or pre-
ented with cardiogenic shock were excluded. This study
as approved by the local institutional review board.
evascularization and pharmacologic treatment. The
ecision to perform PCI or CABG was dependent on
hysician and/or patient choice. During the study period,
oronary stenting was performed exclusively with DES (16).
he PCI was performed according to current practice
uidelines. The choice of the specific type of DES (i.e.,
irolimus-eluting stents [Cypher and Cypher Select, Cordis,
ohnson & Johnson, Bridgewater, New Jersey] or paclitaxel-
luting stents [Taxus Express and Taxus Liberté, Boston
cientific, Natick, Massachusetts]) was left to the operator’s
iscretion. At this time, second-generation DES (i.e.,
otarolimus-, everolimus-, or biolimus-eluting stents) were
ot available to the treating physicians. Antiplatelet therapy
nd periprocedural anticoagulation followed standard regi- pens. After the procedure, pa-
ients were prescribed aspirin in-
efinitely and clopidogrel for at
east 6 months, regardless of
ES type (5). Treatment beyond
his duration was at the discre-
ion of the physician. Surgical
evascularization was performed
sing standard bypass tech-
iques; whenever possible, the
nternal thoracic artery was pref-
rentially utilized for revascular-
zation of the left anterior de-
cending artery (LAD). When
ossible, complete revasculariza-
ion was performed using arterial
onduits or saphenous vein grafts.
tudy outcomes and follow-
p. The end points of the study
ere death; the composite of death, MI, or stroke; and
epeat revascularization. Death was defined as death from
ny cause. The diagnosis of acute MI were defined as either
omplications at the index admission (defined as new
athologic Q waves after index treatment) or follow-up MI
equiring subsequent hospitalizations (defined as an emer-
ency admission with a principal diagnosis of MI), as
escribed previously (8). Stroke, as indicated by neurological
eficits, was confirmed by a neurologist on the basis of
maging studies. Repeat revascularization included target-
essel revascularization, regardless of whether the procedure
as clinically- or angiographically-driven, and nontarget-
essel revascularization. In the DES group, stent thrombosis
as defined as the definite or probable events, according to
he Academic Research Consortium classification (17). All
utcomes of interest were carefully verified and adjudicated
y independent clinicians.
Clinical, angiographic, procedural or operative, and out-
ome data were prospectively recorded in the dedicated PCI
nd surgical databases by independent research personnel.
linical follow-up was performed at 1 month, 6 months,
nd 1 year, and then annually thereafter, by office visit or
elephone contact. For validation of complete follow-up
ata regarding mortality, information about vital status was
btained through January 31, 2010, from the National
opulation Registry of the Korea National Statistical Office
sing a unique personal identification number.
tatistical analysis. Treatment-related differences in long-
erm outcomes between the 2 procedures were analyzed in
ll patients, as well as in high-risk clinical subsets (patients
ith diabetes, patients with abnormal left ventricular ejec-
ion fractions 50%, and patients older than 65 years of
ge), and in anatomic subgroups according to 2- or 3-vessel
isease and the presence or absence of proximal LAD
isease, and left main disease.
The prevalence rates of risk factors and characteristics of the
Abbreviations
and Acronyms
CABG  coronary artery
bypass graft surgery
CAD  coronary artery
disease
CI  confidence interval
DES  drug-eluting stent(s)
EuroSCORE  European
System for Cardiac
Operative Risk Evaluation
HR  hazard ratio
LAD  left anterior
descending artery
MI  myocardial infarction
PCI  percutaneous
coronary interventionatients in the 2 treatment groups were compared with the
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DES Versus CABG for Multivessel Disease January 11, 2011:128–37test or Wilcoxon rank-sum tests (continuous variables) and
ith the chi-square statistics or Fisher exact test (categorical
ariables). Survival curves were constructed using Kaplan-
eier estimates and compared with the log-rank test.
Differences in risk-adjusted, long-term rates of study out-
omes between patients undergoing the 2 procedures were
ssessed using multivariable Cox proportional-hazards regres-
ion (18). Adjusted covariates included the patient’s age and
ex, the presence or absence of a variety of clinical and
oexisting conditions, left ventricular function, and the number
Baseline Characteristics of the Patients AccordTable 1 Baseline Characteristics of the Pat
Variable
Age, yrs
55
55 to 64
65
Median age, yrs
Sex
Male
Female
Body mass index, kg/m2
Medically-treated diabetes
Any
Requiring insulin
Hypertension
Current smoker
Hyperlipidemia
Previous coronary angioplasty
Previous congestive heart failure
Moderate or severe chronic obstructive pulmonary disease
Cerebrovascular or carotid artery disease
Peripheral vascular disease
Renal failure
Prior myocardial infarction
1 to 7 days before treatment
8 days before treatment
No prior myocardial infarction
Electrocardiographic findings
Sinus rhythm
Atrial fibrillation
Other
Ejection fraction
30%
30% to 40%
40% to 50%
50%
Data missing
Median ejection fraction (%)
2-vessel disease
With proximal LAD disease
Without proximal LAD disease
3-vessel disease
With proximal LAD disease
Without proximal LAD disease
Left main disease
Total occlusionData are n (%) or mean  SD.
CABG  coronary artery bypass graft surgery; DES  drug-eluting stent(s);nd the extent of diseased vessels. The proportional hazards
ssumption was confirmed by examination of log (log [sur-
ival]) curves and by testing of partial (Schoenfeld) residuals,
nd no relevant violations were found. To reduce the impact of
reatment selection bias and potential confounding in an
bservational study, we also performed rigorous adjustment for
aseline differences by use of the weighted Cox proportional-
azards regression models with the inverse-probability-of-
reatment weighting (19). With that technique, the weights for
atients undergoing CABG were the inverse of (1  propen-
TreatmentAccording to Treatment
ES (n  1,547) CABG (n  1,495) p Value
0.88
357 (23.1) 299 (20.0)
525 (33.9) 593 (39.7)
665 (43.0) 603 (40.3)
63.0 63.0 0.46
0.02
1,073 (69.4) 1,095 (73.2)
474 (30.6) 400 (26.8)
25.1 2.9 24.8 3.0 0.02
489 (31.6) 402 (26.9) 0.004
86 (5.6) 76 (5.1) 0.56
883 (57.1) 716 (47.9) 0.001
457 (29.5) 502 (33.6) 0.02
373 (24.1) 474 (31.7) 0.001
270 (17.5) 149 (10.0) 0.001
22 (1.4) 68 (4.5) 0.001
16 (1.0) 28 (1.9) 0.05
85 (5.5) 167 (11.2) 0.001
56 (3.6) 86 (5.8) 0.005
42 (2.7) 87 (5.8) 0.001
0.001
138 (8.9) 84 (5.6)
18 (1.2) 210 (14.0)
1,391 (89.9) 1,201 (80.3)
0.02
1,458 (94.2) 1,440 (96.3)
48 (3.1) 26 (1.7)
41 (2.7) 29 (1.9)
0.001
14 (0.9) 49 (3.3)
33 (2.2) 97 (6.6)
144 (9.5) 180 (12.2)
1,317 (87.3) 1,147 (77.9)
39 (2.5) 22 (1.5) 0.04
60.0 59.0 0.001
868 (56.1) 343 (22.9) 0.001
319 (20.6) 146 (9.8) 0.001
549 (35.5) 197 (13.2) 0.001
679 (43.9) 1152 (77.1) 0.001
282 (18.2) 658 (44.0) 0.001
397 (25.7) 494 (33.0) 0.001
178 (11.5) 372 (24.9) 0.001
110 (7.1) 656 (43.9) 0.001ing toients
DLAD  left anterior descending artery.
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January 11, 2011:128–37 DES Versus CABG for Multivessel Diseaseity score), and weights for patients receiving stenting were the
nverse of the propensity score. The propensity scores were
stimated without regard to outcomes, using multiple logistic
egression analysis. A full nonparsimonious model was devel-
ped, which included all the variables shown in Table 1. Model
iscrimination was assessed with c-statistics, and model cali-
ration was assessed with Hosmer-Lemeshow statistics. For
ach clinical or anatomic group, a separate propensity for PCI
ersus CABG was derived.
In addition, outcomes were analyzed on the basis of the
uroSCORE (European System for Cardiac Operative
isk Evaluation) value and the SYNTAX (Synergy Be-
ween PCI With Taxus and Cardiac Surgery) score. The
uroSCORE value has been widely accepted as a clinical-
coring algorithm, with increasing values reflecting a higher
redicted operative mortality (20); a low score was defined as
to 2, an intermediate score as 3 to 6, and a high score as6.
he SYNTAX score reflects a comprehensive anatomical
ssessment, with higher scores indicating more complex coro-
ary disease (10); a low score was defined as 22, an inter-
ediate score as 23 to 32, and a high score as33. SYNTAX
cores were calculated at the core laboratory (21).
All reported p values are 2-sided, and p values 0.05
ere considered statistically significant. No adjustment was
erformed for multiple testing in several subgroups. The
AS software, version 9.1 (SAS Institute, Cary, North
arolina) and the R programming language were used for
tatistical analyses.
esults
atient characteristics. From January 2003 through De-
ember 2005, 3,042 patients with multivessel CAD under-
ent PCI with DES (n  1,547) or CABG (n  1,495).
he baseline characteristics of the study patients are listed in
able 1. The CABG patients had higher clinical and
ngiographic risk profiles than the PCI patients. The
rocedural characteristics of the patients in the Asan-
ultivessel registry have been described previously (5), and
elected features are as follows: 1) among PCI patients, 79%
eceived sirolimus-eluting stents and 21% received
aclitaxel-eluting stents; 2) the mean number of stents was
.8  1.2, and the mean total length of stents and the
verage stent diameter per patient were 65.6  31.5 mm
nd 3.2  0.3 mm, respectively; 3) among CABG patients,
1% underwent off-pump surgery; and 4) 95% underwent
evascularization of the LAD with an arterial conduit.
ollow-up and outcomes. The median follow-up was 5.6
ears (interquartile range: 4.6 to 6.3 years) for the overall
atients. Complete follow-up for major clinical events was
btained in 97.4% of the overall cohort (97.7% for the DES
roup and 97.0% for the CABG group, p  0.20). During
verall follow-up, 304 patients (10.0%) died, of whom 149
4.9%) died of a cardiovascular cause. A total of 56 (1.8%)
ad an acute MI, and 92 (3.0%) had a stroke. Repeat
evascularization was performed in 346 patients (11.4%).Figure 1 Kaplan-Meier Curves of 5-Year Outcomes
for Overall Patients Who Received DES or CABG
(A) Overall survival. (B) Freedom from death, myocardial infarction (MI), or
stroke. (C) Repeat revascularization. CABG  coronary artery bypass graft sur-
gery (red line); DES  drug-eluting stent(s) (blue line).
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DES Versus CABG for Multivessel Disease January 11, 2011:128–37During 5 years of follow-up, the observed (unadjusted)
vent-free survival curve and the crude and adjusted relative
isk according to treatment approach are presented in Figure 1
nd Table 2. In the overall population, unadjusted rates of
eath and the composite of death, MI, or stroke were signif-
cantly lower in the DES group than in the CABG group,
hereas the rate of revascularization was significantly higher in
he DES group. After adjustment for baseline differences using
ultivariable-adjusted Cox regression analysis and the inverse-
robability-of-treatment weighting, the 5-year risks of death
nd the composite of death, MI, or stroke were similar in the
groups. However, the adjusted risk of revascularization
emained consistently higher in the DES group.
We also assessed the relative treatment effects in subsets
f patients with major high-risk clinical factors, including
iabetes mellitus, abnormal ventricular function, and age
65 years (Table 2). In these clinical subsets, there were no
ignificant differences in the 5-year, adjusted rates of death,
nd the composite of death, MI, or stroke between the 2
roups, but the rate of repeat revascularization was consis-
ently higher after DES treatment.
Table 3 presents unadjusted and adjusted hazard ratios for
utcomes according to several anatomic groups. There were no
ignificant differences of treatment effect in the rates of death
nd the composite of death, MI, or stroke among all subsets of
atients with 3-vessel disease. These findings were consistent
or patients with left main disease. However, in patients with
-vessel disease, the adjusted risk of mortality was significantly
ower in the DES group than in the CABG group. These
rends were more prominent in patients with 2-vessel disease
azard Ratios for Clinical Outcomes After DES as Compared With An the Overall P pulat on and in S lected Major Clinical SubgroupsTable 2 Hazard Ratios for Clinical Outcomes After DES as Comin the Overall Population and in Selected Major Clinica
Outcome
No. of Patients/
Total No. of Events Unad
DES CABG Hazard Ratio (9
Overall cohort (n  3,042) 1,547 1,495
Death 129 175 0.75 (0.60–0
Composite outcome (death, MI, or stroke) 165 226 0.73 (0.59–0
Repeat revascularization 259 87 3.35 (2.62–4
Diabetes mellitus (n  891) 489 402
Death 57 60 0.82 (0.57–1
Composite outcome (death, MI, or stroke) 68 72 0.79 (0.57–1
Repeat revascularization 91 22 3.88 (2.43–6
Abnormal LV function (n  517) 191 326
Death 30 66 0.78 (0.51–1
Composite outcome (death, MI, or stroke) 36 82 0.74 (0.50–1
Repeat revascularization 38 9 8.40 (4.04–1
Age 65 yrs (n  1,268) 665 603
Death 84 108 0.73 (0.55–0
Composite outcome (death, MI, or stroke) 101 129 0.71 (0.55–0
Repeat revascularization 96 23 4.31 (2.73–6
Hazard ratios are for the DES group relative to the CABG group. †Hazard ratios are adjusted for ag
isease, cerebrovascular or carotid disease, peripheral arterial disease, and renal failure; history
nvolvement of the proximal left anterior descending artery or left main artery, and total obstructi
CI  confidence interval; LV  left ventricle; MI  myocardial infarction; other abbreviations asithout proximal LAD disease. In each of these anatomic pubgroups, patients undergoing CABG also had lower rates of
epeat revascularization.
Of the 1,547 patients who received DES, 42 had definite
r probable stent thrombosis. Among them, 1 patient had
arly thrombosis, 14 had late thrombosis, and 27 had very
ate thrombosis. At 5-year follow-up, the cumulative inci-
ence of definite or probable stent thrombosis associated
ith DES was 2.6%.
utcomes according to the EuroSCORE and SYNTAX
core. The mean EuroSCORE value was 3.3  2.4 in the
ES group and 3.9 2.5 in the CABG group (p 0.001).
here were no significant differences in observed (unadjusted)
ates of death and the composite of death, MI, or stroke
etween 2 treatment groups in patients with low-risk and
igh-risk EuroSCORE values, except that these outcomes
ere better with DES in patients with intermediate Euro-
CORE (Fig. 2, Table 4). After adjustment of other covari-
tes, the risks of death and serious composite outcomes did not
ignificantly differ. The rate of repeat revascularization was
onsistently higher after DES treatment.
During the study enrollment period, the SYNTAX score
lgorithm was not available for the physician. A retrospective
etrieval of a baseline angiogram for a detailed measurement of
he SYNTAX score was available in 1,915 patients (63%) of
he overall cohort (91% in the DES group and 35% in the
ABG group). The mean SYNTAX score was significantly
ower in the DES group than in the CABG group (17.4 7.8
nd 29.9  10.6, respectively; p  0.001). The observed,
ong-term risk of death and the composite of death, MI, or
troke were similar between the 2 treatment groups among
CABGtients*Wi h After CABG
groups of Patients*
Multivariable Adjusted†
Adjusted by Inverse-Probability-
of-Treatment Weights
I) p Value Hazard Ratio (95% CI) p Value Hazard Ratio (95% CI) p Value
0.01 1.00 (0.76–1.32) 0.99 0.92 (0.70–1.20) 0.54
0.002 0.97 (0.76–1.24) 0.81 0.90 (0.91–1.14) 0.40
0.001 2.93 (2.20–3.90) 0.001 2.78 (2.08–3.71) 0.001
0.28 1.12 (0.72–1.76) 0.61 1.15 (0.73–1.80) 0.54
0.17 1.23 (0.81–1.85) 0.34 1.20 (0.80–1.81) 0.38
0.001 3.28 (1.94–5.54) 0.001 3.48 (1.97–6.14) 0.001
0.27 1.21 (0.70–2.09) 0.49 0.89 (0.54–1.48) 0.66
0.13 1.15 (0.70–1.88) 0.59 0.92 (0.58–1.45) 0.71
0.001 9.20 (3.81–22.19) 0.001 9.80 (4.51–21.32) 0.001
0.03 0.92 (0.64–1.32) 0.65 0.77 (0.55–1.09) 0.14
0.01 0.99 (0.71–1.37) 0.94 0.81 (0.59–1.11) 0.20
0.001 4.57 (2.66–7.87) 0.001 4.28 (2.48–7.38) 0.001
diabetes mellitus; presence or absence of congestive heart failure, chronic obstructive pulmonary
history of MI before procedure; ejection fraction; 2- or 3-vessel disease, presence or absence of
le 1.fterof Papared
l Sub
justed
5% C
.94)
.89)
.28)
.17)
.11)
.20)
.21)
.10)
7.51)
.97)
.93)
.81)
e; sex;
or noatients with low and high scores, except that these outcomes
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January 11, 2011:128–37 DES Versus CABG for Multivessel Diseaseere better for DES in patients with intermediate scores
Fig. 3, Table 4). After adjustment of other covariates, the risks
f death and serious composite outcomes were similar, al-
hough adjusted hazard ratios nonsignificantly favor CABG in
atients with high SYNTAX scores. The advantage of CABG
as quite consistent for repeat revascularization.
iscussion
n this large cohort of patients with multivessel CAD, the
linical judgment ensured that risk-adjusted, long-term
5-year) rates of death and the composite outcome of death,
I, or stroke were similar between DES and CABG. The
ate of repeat revascularization was significantly lower in the
ABG group than in the DES group. These results were
onsistent among patients with high-risk clinical and ana-
omic subsets. In contrast, DES implantation showed a
elative mortality benefit compared with CABG in patients
azard Ratios for Clinical Outcomes After DES as Compared With ATable 3 Hazard Ratios for Clinical Outcomes After DES as Com
Outcome
No. of Patients/
Total No. of Events U
DES CABG Hazard Rati
3-vessel disease
Overall 679 1,152
Death 75 136 0.99 (0.7
Composite outcome (death, MI, or stroke) 87 182 0.83 (0.6
Repeat revascularization 115 59 3.93 (2.8
With proximal LAD disease 282 658
Death 35 90 0.96 (0.6
Composite outcome (death, MI, or stroke) 40 111 0.86 (0.6
Repeat revascularization 48 27 4.63 (2.8
Without proximal LAD disease 397 494
Death 40 46 1.13 (0.7
Composite outcome (death, MI, or stroke) 47 71 0.84 (0.5
Repeat revascularization 67 32 3.31 (2.1
2-vessel disease
Overall 868 343
Death 54 39 0.58 (0.3
Composite outcome (death, MI, or stroke) 78 44 0.75 (0.5
Repeat revascularization 144 28 2.32 (1.5
With proximal LAD disease 319 146
Death 20 15 0.62 (0.3
Composite outcome (death, MI, or stroke) 30 16 0.89 (0.4
Repeat revascularization 51 13 1.94 (1.0
Without proximal LAD disease 549 197
Death 34 24 0.55 (0.3
Composite outcome (death, MI, or stroke) 48 28 0.67 (0.4
Repeat revascularization 93 15 2.61 (1.5
Left main disease 178 372
Death 18 47 0.82 (0.4
Composite outcome (death, MI, or stroke) 20 62 0.67 (0.4
Repeat revascularization 23 23 2.27 (1.2
Hazard ratios are for the DES group relative to the CABG group. †Hazard ratios are adjusted for ag
erebrovascular or carotid disease, peripheral arterial disease, and renal failure; history or no h
nvolvement of the proximal LAD artery or left main artery, and total obstruction.
Abbreviations as in Tables 1 and 2.ith relatively less complex CAD, such as 2-vessel disease. oSeveral observational studies comparing DES and CABG
or multivessel revascularization have shown inconsistent
ndings (4–9,13). Some studies indicated that mortality or
afety outcomes were similar in the 2 groups (5–7,13);
thers registries found a lower rate of survival after PCI with
ES than after CABG (4,8,9). The effect of unmeasured
onfounding related to case selection may explain the
iscordance between these registry results. The SYNTAX
rial represent the most current and applicable evidence on
ultivessel revascularization (10). Although composite
afety (death, MI, or stroke) was comparable at 1 year, the
troke rate was significantly higher in the CABG group,
hereas DES was associated with more frequent revascu-
arization. Recently, 2-year outcomes of the SYNTAX trial
howed a significant increase of MI in PCI patients,
ompared to CABG patients, raising concerns about the
ong-term safety of multivessel DES treatment (22). How-
ver, the average follow-up duration in these clinical and
CABG According to Extent of Diseased Vessels*With After CABG According to Extent of Diseased Vessels*
ted Multivariable Adjusted†
Adjusted by Inverse-Probability-
of-Treatment Weights
CI) p Value Hazard Ratio (95% CI) p Value Hazard Ratio (95% CI) p Value
1) 0.94 1.26 (0.90–1.76) 0.18 1.18 (0.85–1.63) 0.32
7) 0.15 1.06 (0.79–1.43) 0.71 1.00 (0.75–1.34) 0.99
0) 0.001 3.57 (2.48–5.16) 0.001 3.51 (2.46–5.02) 0.001
2) 0.83 1.07 (0.67–1.70) 0.77 1.08 (0.69–1.70) 0.75
3) 0.40 1.05 (0.68–1.61) 0.83 1.06 (0.70–1.60) 0.79
4) 0.001 5.54 (3.02–10.15) 0.001 5.19 (3.09–8.70) 0.001
3) 0.57 1.51 (0.91–2.50) 0.11 1.40 (0.86–2.27) 0.18
2) 0.36 1.09 (0.72–1.67) 0.68 0.97 (0.64–1.47) 0.89
8) 0.001 2.85 (1.78–4.57) 0.001 2.57 (1.58–4.18) 0.001
8) 0.01 0.57 (0.36–0.92) 0.02 0.60 (0.38–0.95) 0.03
9) 0.13 0.74 (0.49–1.14) 0.17 0.80 (0.53–1.20) 0.28
9) 0.001 2.03 (1.30–3.17) 0.002 1.89 (1.19–3.01) 0.008
1) 0.16 0.60 (0.27–1.34) 0.21 0.64 (0.30–1.37) 0.25
4) 0.72 0.91 (0.44–1.89) 0.80 0.97 (0.48–1.96) 0.93
8) 0.03 1.73 (0.87–3.45) 0.12 1.58 (0.81–3.10) 0.18
4) 0.03 0.59 (0.32–1.09) 0.09 0.54 (0.31–0.97) 0.04
7) 0.09 0.67 (0.39–1.15) 0.15 0.66 (0.39–1.10) 0.11
1) 0.001 2.15 (1.19–3.90) 0.01 1.94 (1.04–3.64) 0.04
2) 0.48 0.95 (0.51–1.80) 0.89 1.02 (0.57–1.85) 0.94
1) 0.12 0.88 (0.49–1.58) 0.68 0.87 (0.50–1.51) 0.62
5) 0.006 2.16 (1.11–4.21) 0.02 2.10 (1.12–3.95) 0.02
diabetes; presence or absence of congestive heart failure, chronic obstructive pulmonary disease,
of MI before procedure; ejection fraction; 2-vessel or 3-vessel disease, presence or absence offterpared
nadjus
o (95%
5–1.3
4–1.0
6–5.4
5–1.4
0–1.2
8–7.4
4–1.7
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4–3.4
2–1.2
9–1.6
5–3.5
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0–1.1
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DES Versus CABG for Multivessel Disease January 11, 2011:128–37ooled analysis involving bypass surgery or PCI with bal-
oon angioplasty or bare-metal stents frequently include
atients with follow-up durations of 5 or more years
23,24). So, our study is more long-term comparison of PCI
ith DES and CABG for multivessel CAD and therefore
rovides important information about the sufficiently long-
erm effect of DES relative to CABG.
In the diabetic subgroup of the SYNTAX and ARTS II
Arterial Revascularization Therapies Study–Part II) study
nd the CARDia (Coronary Artery Revascularization in
iabetes) trial, the mortality and safety composite were
imilar between the 2 treatments, whereas revascularization
as significantly higher in the DES arm, which were
onsistent with our subgroup analysis (6,12,25). A recent
eta-analysis suggests that CABG is associated with lower
Figure 2 Kaplan-Meier Curves of 5-Year Outcomes Among Stud
(A) Outcomes for patients with low-risk EuroSCORE (European System for Cardiac
EuroSCORE (3 to 6). (C) Outcomes for patients with high-risk EuroSCORE (6). CAortality than PCI for patients age 65 years or older (24). sther registry studies also revealed that CABG showed
urvival benefit in elderly patients compared with PCI with
ES or BMS, which were contrary to our findings (8,26).
n real-world clinical practice, it is likely that elderly patients
ith significant comorbidities tend to be more often re-
erred for PCI because of its less invasive nature; thus, it
ight represent the residual effects of selection bias and
therwise unmeasured confounding, contributing to the
iscordant results in elderly patients among several studies.
owever, in our study, sicker patients with higher comor-
idities were referred more to CABG than to DES. In
ddition, owing to the nature of subgroup analysis and the
imited number of patients in each subgroup, these results of
ubgroup analyses must be interpreted with caution and
ust be confirmed with thorough, large clinical trials
ients According to Treatment Group and EuroSCORE Category
tive Risk Evaluation) (0 to 2). (B) Outcomes for patients with intermediate-risk
d line); DES (blue line). Abbreviations as in Figure 1.y Pat
Opera
BG (repecifically targeting high-risk populations.
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January 11, 2011:128–37 DES Versus CABG for Multivessel DiseaseClinical registry studies have reported that patients with the
east extensive CAD have better survival after PCI, whereas
atients with the most extensive disease have better survival
fter CABG (27,28). Similarly, we found that PCI with DES
ad survival benefits over CABG in patients with 2-vessel
isease. Therefore, some subsets of patients will do well or even
etter with DES, whereas other subsets will do better with
ABG, with the extent of CAD being the strongest clinical
actor affecting the choice between CABG and PCI, even in
he DES era. The SYNTAX trial also suggested that PCI
eemed to be even safer than CABG in more simple anatomic
ituations (i.e., low SYNTAX score), whereas the event rate
as significantly lower in the CABG group among patients
ith high scores (10). In our study, the adjusted-risks for death
nd serious composite outcomes nonsignificantly favor CABG
n patients with high SYNTAX score.
Long-term surveillance for stent thrombosis is particu-
arly important, given the high average number of stent and
ong stent length after multivessel PCI with DES. In the
urrent study, we noted a 5-year definite or probable stent
hrombosis incidence of 2.6%, similar or even lower than
azard Ratios for Clinical Outcomes After DES as Compared With Acco ing t Clinical Scoring (EuroSCORE) and Anatomic Scoring (Table 4 Hazard Rati s for Clinical Outcomes After DES as ComAccording to Clinical Scoring (EuroSCORE) and Anatom
Outcome
No. of Patients/
Total No. of Events
DES CABG
EuroSCORE (n  3,042)
Low risk (0 to 2) 666 485
Death 34 26
Composite outcome (death, MI, or stroke) 50 37
Repeat revascularization 119 41
Intermediate risk (3 to 6) 710 800
Death 54 93
Composite outcome (death, MI, or stroke) 70 123
Repeat revascularization 121 39
High risk (6) 171 210
Death 41 56
Composite outcome (death, MI, or stroke) 45 66
Repeat revascularization 19 7
SYNTAX score (n  1,915)
Low risk (22) 1,068 129
Death 74 11
Composite outcome (death, MI, or stroke) 106 12
Repeat revascularization 182 8
Intermediate risk (23 to 32) 274 185
Death 29 32
Composite outcome (death, MI, or stroke) 33 42
Repeat revascularization 42 12
High risk (33) 58 201
Death 8 23
Composite outcome (death, MI, or stroke) 10 27
Repeat revascularization 9 9
Hazard ratios are for the DES group relative to the CABG group. †Hazard ratios are adjusted for ag
erebrovascular or carotid disease, peripheral arterial disease, and renal failure; history or no hist
f the proximal LAD artery or left main artery, and total obstruction.
EuroSCORE  European System for Cardiac Operative Risk Evaluation; SYNTAX  Synergy Betwates reported in several observational studies (29,30). In addition, since second-generation DES show superior safety
nd efficacy to first-generation DES (31,32), the relative
ong-term benefits of new-generation DES compared to
ABG should be reassessed soon for optimal multivessel
evascularization.
tudy limitations. The present study had the limitations
nherent to a nonrandomized, single-center registry study.
espite appropriate statistical adjustments, unknown con-
ounders may have affected the results. Second, for inter-
retation of several clinical and anatomic subgroup analyses,
hese exploratory results are to be considered hypothetical
nd hypotheses-generating only, and should not necessarily
ictate any change in current practice patterns. Also, some
f the multivariable models might be overfitted based on
mall numbers of end point events. Finally, the direct
pplication of our findings to real-life practice predomi-
antly using second-generation DES may be limited.
onclusions
ith optimal clinical judgment of the treating physician for
CABG,AX Score) Systems*With After CABG,
coring (SYNTAX Score) Systems*
Unadjusted Multivariable Adjusted†
d Ratio (95% CI) p Value Hazard Ratio (95% CI) p Value
0 (0.60–1.67) 0.99 1.04 (0.57–1.89) 0.89
4 (0.68–1.60) 0.85 1.14 (0.69–1.88) 0.62
9 (1.74–3.56) 0.001 2.24 (1.49–3.38) 0.001
9 (0.49–0.96) 0.03 0.74 (0.49–1.10) 0.14
6 (0.49–0.88) 0.005 0.73 (0.51–1.04) 0.10
5 (2.88–5.98) 0.001 4.03 (2.62–6.20) 0.001
6 (0.64–1.44) 0.84 1.33 (0.76–2.35) 0.32
5 (0.58–1.24) 0.39 1.19 (0.71–1.98) 0.51
5 (1.49–8.45) 0.004 3.04 (0.91–10.19) 0.07
4 (0.45–1.59) 0.60 1.14 (0.54–2.39) 0.74
2 (0.62–2.03) 0.71 1.25 (0.67–2.28) 0.47
8 (1.47–6.04) 0.003 2.77 (1.31–5.85) 0.008
2 (0.37–1.02) 0.06 0.78 (0.40–1.51) 0.46
2 (0.33–0.82) 0.005 0.74 (0.41–1.33) 0.31
6 (1.29–4.68) 0.006 3.08 (1.44–6.58) 0.004
3 (0.50–2.75) 0.61 1.76 (0.55–5.69) 0.34
0 (0.63–2.68) 0.48 1.64 (0.57–4.75) 0.36
1 (1.62–10.40) 0.003 3.18 (0.94–10.78) 0.06
diabetes; presence or absence of congestive heart failure, chronic obstructive pulmonary disease,
I before procedure; ejection fraction; 2- or 3-vessel disease, presence or absence of involvement
I With Taxus and Cardiac Surgery; other abbreviations as in Tables 1 and 2.fterSYNTpared
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DES Versus CABG for Multivessel Disease January 11, 2011:128–37CI or bypass surgery, DES implantation is associated with
imilar long-term (5-year) rates of death and the composite
nd point of death, MI, or stroke, as compared with CABG.
ates of repeat revascularization were significantly higher
mong patients receiving DES. A large randomized com-
arison with longer-term follow-up of 5 or 10 years will
rovide more confidence in the long-term safety, durability,
nd efficacy of PCI with DES in reference to CABG.
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